By Cecilia Butini

 

Novartis AG said Monday that a trial to evaluate prostate-cancer drug Pluvicto met its primary endpoint in patients with a specific type of metastatic cancer.

The Swiss drug company said the primary endpoint was to improve progression-free survival, or the time in which patients can live without the disease advancing.

The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

December 05, 2022 01:42 ET (06:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Novartis.